Drug-carrying nanoparticles reduced venous malformations in mice
Researchers reported that rapamycin-based nanoparticles carrying ponatinib reduced venous-malformation size by 70% in mouse models after one injection and 20 days. The particles were designed to accumulate in leaky abnormal vessels, but their long-term effect, repeat-dose needs and relevance to people are not yet known.
The story
A team associated with Boston Children's Hospital reported a nanoparticle treatment that reduced venous-malformation size in mice. Venous malformations are abnormally formed veins linked to excessive growth of cells lining blood vessels; they may enlarge as children grow. The researchers designed particles from a new form of rapamycin, rather than using an inert carrier, and loaded the particles with the drug ponatinib. Their approach was based on an observation that nanoparticles used as contrast dye had remained inside a different vascular malformation for two months, suggesting that abnormal vessels can be leaky and retain such particles. In mouse models of venous malformations, the team injected the drug-loaded particles and compared outcomes with mice that received both medicines orally. After 20 days, the formulation containing bundled rapamycin nanoparticles plus ponatinib had the largest reported effect, reducing lesion size by 70% after one injection. The study, by Weimin Tang and colleagues, was published in Science Translational Medicine. The report describes a preclinical result only; it does not say that the treatment has been tested in people.
Why it matters
For people with large venous malformations, available choices can be constrained: surgery may pose excessive bleeding risk, while medicines used to slow lesion growth can cause side effects when taken regularly. The tested formulation aims to exploit the leakiness of abnormal vessels so treatment accumulates at the lesion rather than being delivered only as circulating oral drugs. If later studies support that premise, it could inform a way to deliver more than one therapy together. At present, however, the concrete consequence is a candidate strategy for further preclinical and clinical evaluation, not a new treatment option.
Evidence and context
Venous malformations are vascular malformations in which abnormal veins can enlarge as a child grows. The source says they may range from small and superficial lesions to conditions that are disfiguring, debilitating or life-threatening, and can interfere with breathing, swallowing or movement. Existing management can include surgery, but large lesions may be too risky to remove because of blood-loss concerns. Patients may also receive drugs such as rapamycin to limit cell growth and enlargement, yet regular use can bring side effects that lead some patients to discontinue treatment. The reported work tests whether drug delivery concentrated in the abnormal vessels could address that treatment constraint.
Limits and unknowns
This is an early animal-model result, not evidence that the formulation is safe or effective in people. The reported 70% reduction was observed over 20 days after one injection, so long-term durability, toxicity, dosing and whether repeat injections are needed remain unresolved. The source also does not report a human trial, a comparison with surgery, or patient outcomes. Although the formulation is intended to concentrate treatment in abnormal vessels, the article does not establish that it will reduce side effects in clinical use.
Follow the story
Share it, watch the explainer, or continue with the reporting trail.
Further reading on this topic
2 links
Drug-carrying nanoparticles reduced venous malformations in mice
A short visual explainer for readers who want the story in a different rhythm.
Highlights
- Nanoparticles reduce venous malformations in mice
- Targeted drug delivery to abnormal vessels
- Single injection leads to significant lesion shrinkage
- Potential for fewer side effects with targeted therapy
Transcript
Researchers developed rapamycin-based nanoparticles carrying ponatinib that reduced venous malformations by 70% in mice.
These particles target leaky abnormal vessels, concentrating treatment directly where it’s needed in the lesion.
After one injection, lesion size shrank significantly over 20 days compared to oral drug treatments.
This approach may reduce side effects by limiting drug exposure outside the affected vessels.
While still preclinical, this method offers a promising new direction for treating large venous malformations.